Catalysts / IKT
Upcoming FDA decisions and readouts we track for Inhibikase Therapeutics, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Inhibikase Therapeutics (IKT, listed on Nasdaq). Both concern IKT-001 (imatinib prodrug) (Pulmonary arterial hypertension — interim safety (n=50); Pulmonary arterial hypertension — PVR reduction (n=120)).
First on the list: the Phase 3 readout for IKT-001 (imatinib prodrug) (Pulmonary arterial hypertension — interim safety (n=50)), guided by the company to H1 2027. By stage, the upcoming rows are 2 Phase 3 readouts.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: How to read a Phase 3 topline readout.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics IKT · Nasdaq | IKT-001 (imatinib prodrug) | Pulmonary arterial hypertension — interim safety (n=50) | H1 2027 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | No |
| Inhibikase Therapeutics IKT · Nasdaq | IKT-001 (imatinib prodrug) | Pulmonary arterial hypertension — PVR reduction (n=120) | Mid 2028 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | No |
FreeBioList